Skip to main content
Monday, November 16, 2026Nov 16

More cancer success with drugs that enlist immune system

John Ryan poses for a photo in his office at his house in Aldie, Va., Friday, May 29, 2015. For the first time, a major study has shown that a drug targeting the body's disease-fighting immune system may improve survival for the most common form of lung cancer. Ryan was diagnosed with incurable lung cancer two years ago. Standard cancer medicine left him exhausted, prone to infections and did little to shrink the tumor. In October 2013 he joined the immunotherapy study and was randomly assigned to get Opdivo. Three months later his tumor had been reduced by 65 percent and he felt well enough to help his son cut down a large tree for firewood. (AP Photo/Manuel Balce Ceneta)
John Ryan poses for a photo in his office at his house in Aldie, Va., Friday, May 29, 2015. For the first time, a major study has shown that a drug targeting the body's disease-fighting immune system may improve survival for the most common form of lung cancer. Ryan was diagnosed with incurable lung cancer two years ago. Standard cancer medicine left him exhausted, prone to infections and did little to shrink the tumor. In October 2013 he joined the immunotherapy study and was randomly assigned to get Opdivo. Three months later his tumor had been reduced by 65 percent and he felt well enough to help his son cut down a large tree for firewood. (AP Photo/Manuel Balce Ceneta)

CHICAGO (AP) – For the first time, a major study shows that a drug targeting the body’s disease-fighting immune system may improve survival for the most common form of lung cancer.

These newer kinds of drugs have transformed treatment of melanoma, the deadliest kind of skin cancer. Studies presented at a conference Friday suggest these “immune therapies” can play a broader role in more common cancers, including lung, liver, colon and head and neck.

Doctors also may have found a way to help predict which patients would respond best to one of these newer treatments, according to research presented at the Chicago meeting. Immune therapy drugs are aimed at helping the body’s immune system recognize and attack cancer.

The lung cancer study tested Bristol-Myers Squibb’s Opdivo (op-DEE-voh), which blocks a protein that prevents the immune system from attacking cancer cells. It worked better than chemotherapy for patients with a form of non-small cell lung cancer that is diagnosed in more than 120,000 people nationwide each year.

Opdivo, also called nivolumab, was approved in March for a less common form of lung cancer, and late last year for melanoma. Two other immunotherapies are approved for melanoma – Keytruda and Yervoy.